Glycated hemoglobin level is significantly associated with the severity of coronary artery disease in non-diabetic adults
- Anping Cai†1,
- Guang Li†1,
- Jiyan Chen1,
- Xida Li1,
- Xuebiao Wei1,
- Liwen Li1Email author and
- Yingling Zhou1
© Cai et al.; licensee BioMed Central Ltd. 2014
Received: 18 September 2014
Accepted: 30 November 2014
Published: 4 December 2014
To investigate relationship between glycated hemoglobin (HbA1c) level and coronary artery disease (CAD) severity.
Observational study was conducted and 573 participants were enrolled and baseline characteristics were collected. Clinical presentations in terms of stable angina, unstable angina or acute myocardial infarction were diagnosed. All participants were performed coronary angiography to figure out the numbers of coronary artery stenosis in terms of none-stenosis (< 50% stenosis), single or multiple vessels stenoses (≥ 50% stenosis). All participants were divided into subgroups according to two categories in terms of severity of clinical presentation (stable angina, unstable angina, or acute myocardial infarction) and the number of coronary artery stenosis (none, single, and multiple vessels). Primary endpoint was to evaluate relationship between baseline HbA1c value and CAD severity.
Consistent to previous studies, participants with CAD had more risk factors such as elderly, smoking, low HDL-C and high CRP levels. Notably, HbA1c level was more prominent in CAD group than that without CAD. As compared to stable angina subgroup, HbA1c levels were gradually increased in unstable angina and acute myocardial infarction groups. Similar trend was identified in another category in terms of higher HbA1c level corresponding to more vessels stenoses. Multivariate regression analyses showed that after adjusted for traditional risk factors as well as fasting blood glucose, HbA1c remained strongly associated with the severity of CAD. Nonetheless, there was no significant association when CRP was accounted for.
HbA1c may be a useful indicator for CAD risk evaluation in non-diabetic adults.
KeywordsGlycated hemoglobin Coronary artery disease Diabetes mellitus
Diabetes mellitus is a major and well established risk factor for macro-vascular diseases such as atherosclerotic cardiovascular diseases (ASCVD) and micro-vascular diseases such as neural, renal and retinal diseases [1, 2]. Of note, in patients with diabetes, plasma glucose level is significantly associated with the incidence and severity of micro-vascular and macro-vascular complications . Currently, owing to its advantages over fasting blood glucose such as low intra-individual variability and being capable of evaluating the long-term blood glucose control [3, 4], glycated hemoglobin (HbA1c), a parameter of average blood glucose levels over 12 weeks, has also been suggested using in clinical practice currently [5, 6]. Evidence from epidemiological studies also showed that as compared to fasting blood glucose, HbA1c was more strongly associated with the risks of ASCVD and mortality from any causes [7, 8], which further supported the notion that HbA1c was superior to fasting blood glucose in predicting ASCVD outcomes. Nevertheless, some drawbacks regarding HbA1c, including un-satisfactory correlation with fasting blood glucose and over-diagnosis among patients with anemia and renal dysfunction, have also aroused concerns with respect to its application for diabetic diagnosis and ASCVD risk prediction [9, 10]. And the truly relationship between HbA1c and cardiovascular outcomes in populations without diabetes are still uncertain. For example, Silbernagel et al. reported that HbA1c significantly and independently of fasting blood glucose predicted all-cause of cardiovascular death in white population without diabetes . Garg N and colleagues showed that in non-diabetics, HbA1c level has a linear incremental association with ASCVD . Nonetheless, data from the Emerging Risk Factors Collaboration revealed that HbA1c merely added little incremental benefit for ASCVD risk prediction in patients without known ASCVD and diabetes .
In light of previous findings, our current study was designed to evaluate whether HbA1c level was associated with the severity of coronary artery diseases (CAD) in populations without diagnostic diabetes, and we believed that the clinical implication of our study would add, if any, valuable information to address whether HbA1c level could be used to predict the ASCVD risk in non-diabetic population.
Studied populations and protocols
Studied populations were enrolled from June of 2013 to April of 2014 after informed consent was obtained, and this study was approved by the Ethical Committee of Guangdong General Hospital. Current research is a retrospective and observational research, therefore, the including criteria are subjects with definitive coronary artery condition in terms of none-significant, single or multiple vessels stenoses as assessed by angiographic examination, and the excluding criteria are subjects without angiographic examination, with significant hepatic or renal dysfunction, anemia, tumor or connective tissue diseases. Clinical presentations in terms of stable angina, unstable angina or acute myocardial infarction were diagnosed according to their clinical manifestation, electrocardiography characteristics and cardiac biomarkers by two experts of cardiology. All participants were performed coronary angiography to definitely figure out the numbers of coronary artery stenosis in terms of none-significant (< 50% stenosis), single or multiple vessels stenoses (≥ 50% stenosis). Baseline characteristics including age, gender, family history of ASCVD, smoking status, hypertension, serum levels of lipid profile, fasting blood glucose, C-reactive protein (CRP) and HbA1c were collected at admission. In order to better understand whether HbA1c level was associated with the severity of CAD, all participants were divided into different subgroups according to two major categories in terms of the severity of clinical presentation (stable angina, unstable angina, or acute myocardial infarction) and the number of coronary artery stenosis (none, single, and multiple vessels stenoses).
The primary endpoint of current study was to evaluate the relationship between HbA1c level and the severity of CAD. In addition, whether HbA1c was an independent risk indicator for the severity of CAD was also evaluated.
Continuous data was presented as mean ± SD or median (interquartile range) appropriately, and compared by the Student’s t-test when data was normally distributed, otherwise compared by the Wilcoxon rank-sum test. Categorical data was presented as percentage and compared by χ2 test. Univariate and multivariate regression analyses were performed to evaluate the relationship between HbA1c value and the severity of coronary artery diseases. Statistical analyses were performed by using SPSS software version 16.0 (SPSS, Inc., Chicago, Illinois). A value of p < 0.05 was considered significant.
Without CAD (n = 107)
CAD (n = 466)
60.5 ± 12.1
63.83 ± 11.0
Family history (%)
1.51 ± 1.05
1.78 ± 1.50
4.44 ± 1.01
4.30 ± 1.13
2.67 ± 0.87
2.62 ± 0.99
1.11 ± 0.30
0.97 ± 0.23
1.24 ± 0.39
1.10 ± 0.31
0.81 ± 0.60
0.77 ± 0.23
3.67 ± 0.60
12.12 ± 1.21
96.5 ± 10.1
97.2 ± 8.8
6.60 ± 1.33
6.82 ± 1.07
5.58 ± 0.76
5.26 ± 0.69
6.05 ± 1.17
6.55 ± 1.38
Comparisons of baseline characteristics of clinical sub-groups
None (n = 129)
Single (n = 87)
Multi (n = 250)
59.7 ± 10.4
61.6 ± 11.3
64.2 ± 9.7
Family history (%)
1.62 ± 0.21
1.71 ± 0.18
1.73 ± 0.22
4.65 ± 1.02
4.59 ± 1.01
4.70 ± 1.05
2.82 ± 0.62
2.84 ± 0.55
2.86 ± 0.57
1.08 ± 0.26
0.99 ± 0.24
0.95 ± 0.20
1.29 ± 0.41
1.22 ± 0.36
1.13 ± 0.43
0.82 ± 0.56
0.80 ± 0.35
0.80 ± 0.47
9.24 ± 1.08
10.86 ± 1.12
13.65 ± 1.17
96.8 ± 8.1
97.0 ± 6.4
97.6 ± 8.2
6.67 ± 1.03
6.80 ± 1.01
6.82 ± 1.03
5.22 ± 0.44
5.26 ± 0.38
5.29 ± 0.62
Comparison of HbA1c levels among subgroups of CAD
Multivariate regression analyses
For the purpose of investigating whether HbA1c was an independent risk factor for the severity of CAD, multivariate regression analyses were performed. In the first category, after adjustment for age, gender, family history of CAD, smoking and hypertension (in model 1a), HbA1c was strongly associated with the severity of CAD (P for trend = 0.010). Additional adjustment for TC, HDL-C, ApoA, and fasting blood glucose, the association was attenuated but HbA1c remained significantly associated with the severity of CAD (P for trend = 0.043, in model 1b). Notably, with adjustment for CRP (P for trend = 0.265, in model 1c), there was no significant association between HbA1c and the severity of CAD. In the second category, after adjustment for age, gender, family history of CAD, smoking and hypertension (in model 2a), there was a strongly relationship between HbA1c and the number of coronary artery stenosis (P for trend < 0.001). Additional adjustment for TC, HDL-C, ApoA, and fasting blood glucose (in model 2b), HbA1c remained strongly associated with the number of coronary artery stenosis (P for trend < 0.001). Similarly, with adjustment for CRP (P for trend = 0.168, in model 2c), there was no significant association between HbA1c and the number of coronary artery stenosis.
Currently, the predictive value of HbA1c on ASCVD risk in non-diabetic population is still less certain, and the application of HbA1c on ASCVD risk assessment among different Cardiovascular Society is also still inconsistent. Findings from our current study show that there is a significant association between HbA1c level and the severity of CAD in non-diabetic population, even after adjustment for traditional risk factors, and this relationship is independent of fasting blood glucose. Nonetheless, we also observed that after adjustment for CRP, there was no significant association between HbA1c and the severity of CAD.
Knowingly, glycated hemoglobin is a stable parameter reflecting approximately 3 months of blood glucose levels and it has now been suggested using in clinical practice for long-term blood glucose assessment in diabetic patients [1, 13]. HbA1c is calculated as the ratio of glycated to non-glycated N-terminal peptide of hemoglobin, and the HbA1c level has been universally recognized as important indicator for micro-vascular complications in diabetic patients [13, 14]. Nevertheless, whether HbA1c level could also be used in macro-vascular diseases (such as ASCVD) risk prediction is less clear, especially in non-diabetic populations [15, 16].
Accordingly, ASCVD is the leading cause of morbidity and mortality worldwide and improvement of risk discrimination is imperative . Previously, results from previous studies showed that for coronary heart diseases, risk discrimination was significantly enhanced when HbA1c was added in risk algorithm in non-diabetic patients [8, 18, 19]. Our current study also showed that as compared to stable episode (stable angina), the levels of HbA1c were gradually and significantly increased in unstable conditions in terms of unstable angina and acute myocardial infarction, indicating that increased HbA1c level might result in atherosclerotic plaque pro-rupture, and to our best knowledge there were some mechanisms might partially explain this finding. Biologically, glycated hemoglobin is an advanced glycosylation end-product, and increased HbA1c level could reflect more generation of advanced glycosylation end-product, which might subsequently abundantly attached to vessel wall causing endothelial dysfunction and oxidative stress promotion [20, 21]. On the other hand, the binding of advanced glycosylation end-product might also result in inflammatory cytokines such as CRP over-production . Increased CRP level has been found significantly associated with the instability of plaque [23, 24], and this might partially explain why after adjustment for CRP, there was no significant association between HbA1c and the severity of CAD. Finally, increased advanced glycosylation end-product could interfere with endogenous fibrinolytic system which might result in higher risk of coronary artery stenosis [25, 26]. Future experimental and clinical studies are warranted to investigate whether reduced HbA1c level will improve atherosclerosis plaque stability.
Other than the significant association between HbA1c level and the severity of CAD, our current study also showed that increased HbA1c level was associated with more vessel stenoses in non-diabetic patients. As aforementioned, by means of increasing vascular permeability, promoting endothelium dysfunction, and enhancing inflammation and oxidative reaction, increased advanced glycosylation end-product might lead to more vessels stenoses.
Consistent with previous some epidemiological studies [11, 18, 19, 27], data from our study also revealed that after adjusted for traditional risk factors including age, smoking, TC, HDL-C, HbA1c remained strongly associated with the severity of CAD. Notably, even after adjusted for fasting blood glucose, an independent risk factor for ASCVD and diabetes, there was still significant relationship between HbA1c and the severity of CAD, further supporting previous findings that HbA1c might be superior to fasting blood glucose in the respects of CVD risk discrimination. However, there was one distinctive discrepancy between our research and previous studies [11, 18, 19, 27] were that we concomitantly evaluated the relationship between HbA1c level and CAD severity including clinical scenario severity and the number of coronary artery stenosis.
As compared to fasting blood glucose, HbA1c level reflecting both fasting and post-prandial blood glucose might also partially explain the superiority of HbA1c, because peak plasma glucose level might cause more severe damage to endothelium [28, 29]. Future study is warranted to investigate whether there is significant interaction between post-prandial blood glucose and HbA1c on CVD risk prediction. Notably, there was no significant association between HbA1c and the severity of CAD when adjusted for CRP. The underlying mechanism might be ascribed to the increased CRP release when advanced glycosylated end-product was elevated.
Our observational study found out that in non-diabetic population, HbA1c level was significantly associated with the severity of coronary artery diseases, which further supporting the notion that HbA1c may be a useful and independent indicator for CVD risk evaluation.
This work was supported by the grants from the Technology Project Foundation of Guangdong Province, China (2009A030301004, 2011B031800021, 2011B061300034 and 2011B031800263), Guangdong Natural Science Foundation (S2012010009532), Guangdong Medical Research Foundation (B2011002), Cardiovascular medication grant of Guangdong Province (2011X25), Medical Scientific Research Grant of the Health Ministry of Guangdong province, China (B2011310 and A2012663).
- American Diabetes Association: Standards of medical care in diabetes--2014. Diabetes Care. 2014, 37 Suppl 1: S14-S80.View ArticleGoogle Scholar
- Zamora-Ros R, Forouhi NG, Sharp SJ, Gonzalez CA, Buijsse B, Guevara M, van der Schouw YT, Amiano P, Boeing H, Bredsdorff L, Clavel-Chapelon F, Fagherazzi G, Feskens EJ, Franks PW, Grioni S, Katzke V, Key TJ, Khaw KT, Kuhn T, Masala G, Mattiello A, Molina-Montes E, Nilsson PM, Overvad K, Perquier F, Quiros JR, Romieu I, Sacerdote C, Scalbert A, Schulze M: The association between dietary flavonoid and lignan intakes and incident type 2 diabetes in European populations: the EPIC-InterAct study. Diabetes Care. 2013, 36: 3961-3970. 10.2337/dc13-0877PubMed CentralView ArticlePubMedGoogle Scholar
- Selvin E, Crainiceanu CM, Brancati FL, Coresh J: Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med. 2007, 167: 1545-1551. 10.1001/archinte.167.14.1545View ArticlePubMedGoogle Scholar
- American Diabetes Association: Standards of medical care in diabetes--2009. Diabetes Care. 2009, 32 Suppl 1: S13-S61.View ArticleGoogle Scholar
- Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith SC, Taylor AJ, Weintraub WS, Wenger NK, Jacobs AK, Smith SC, Anderson JL, Albert N, Buller CE, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, Nishimura R, Ohman EM, Page RL: 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. J Am Coll Cardiol. 2010, 56: e50-e103. 10.1016/j.jacc.2010.09.001View ArticlePubMedGoogle Scholar
- Anderson TJ, Gregoire J, Hegele RA, Couture P, Mancini GB, McPherson R, Francis GA, Poirier P, Lau DC, Grover S, Genest J, Carpentier AC, Dufour R, Gupta M, Ward R, Leiter LA, Lonn E, Ng DS, Pearson GJ, Yates GM, Stone JA, Ur E: 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013, 29: 151-167. 10.1016/j.cjca.2012.11.032View ArticlePubMedGoogle Scholar
- Silbernagel G, Grammer TB, Winkelmann BR, Boehm BO, Marz W: Glycated hemoglobin predicts all-cause, cardiovascular, and cancer mortality in people without a history of diabetes undergoing coronary angiography. Diabetes Care. 2011, 34: 1355-1361. 10.2337/dc10-2010PubMed CentralView ArticlePubMedGoogle Scholar
- Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J, Brancati FL: Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010, 362: 800-811. 10.1056/NEJMoa0908359PubMed CentralView ArticlePubMedGoogle Scholar
- Kramer CK, Araneta MR, Barrett-Connor E: A1C and diabetes diagnosis: the Rancho Bernardo study. Diabetes Care. 2010, 33: 101-103. 10.2337/dc09-1366PubMed CentralView ArticlePubMedGoogle Scholar
- Sacks DB: The diagnosis of diabetes is changing: how implementation of hemoglobin A1c will impact clinical laboratories. Clin Chem. 2009, 55: 1612-1614. 10.1373/clinchem.2009.132704View ArticlePubMedGoogle Scholar
- Garg N, Moorthy N, Kapoor A, Tewari S, Kumar S, Sinha A, Shrivastava A, Goel PK: Hemoglobin A(1c) in nondiabetic patients: an independent predictor of coronary artery disease and its severity. Mayo Clin Proc. 2014, 89: 908-916. 10.1016/j.mayocp.2014.03.017View ArticlePubMedGoogle Scholar
- Di Angelantonio E, Gao P, Khan H, Butterworth AS, Wormser D, Kaptoge S, Kondapally Seshasai SR, Thompson A, Sarwar N, Willeit P, Ridker PM, Barr EL, Khaw KT, Psaty BM, Brenner H, Balkau B, Dekker JM, Lawlor DA, Daimon M, Willeit J, Njolstad I, Nissinen A, Brunner EJ, Kuller LH, Price JF, Sundstrom J, Knuiman MW, Feskens EJ, Verschuren WM, Wald N: Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA. 2014, 311: 1225-1233.View ArticlePubMedGoogle Scholar
- American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010, 33 Suppl 1: S62-S69.View ArticleGoogle Scholar
- Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, Heller SR, Rodriguez H, Rosenzweig J, Vigersky R: Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013, 36: 1384-1395. 10.2337/dc12-2480PubMed CentralView ArticlePubMedGoogle Scholar
- Pradhan AD, Rifai N, Buring JE, Ridker PM: Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women. Am J Med. 2007, 120: 720-727. 10.1016/j.amjmed.2007.03.022PubMed CentralView ArticlePubMedGoogle Scholar
- O’Sullivan CJ, Hynes N, Mahendran B, Andrews EJ, Avalos G, Tawfik S, Lowery A, Sultan S: Haemoglobin A1c (HbA1C) in non-diabetic and diabetic vascular patients. Is HbA1C an independent risk factor and predictor of adverse outcome. Eur J Vasc Endovasc Surg. 2006, 32: 188-197. 10.1016/j.ejvs.2006.01.011View ArticlePubMedGoogle Scholar
- Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, 3rd Mohler ER, Moy CS: Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation. 2014, 129: e28-e292. 10.1161/01.cir.0000441139.02102.80View ArticlePubMedGoogle Scholar
- Ashraf H, Boroumand MA, Amirzadegan A, Talesh SA, Davoodi G: Hemoglobin A1C in non-diabetic patients: an independent predictor of coronary artery disease and its severity. Diabetes Res Clin Pract. 2013, 102: 225-232. 10.1016/j.diabres.2013.10.011View ArticlePubMedGoogle Scholar
- Ayhan SS, Tosun M, Ozturk S, Alcelik A, Ozlu MF, Erdem A, Erdem K, Erdem FH, Yazici M: Glycated haemoglobin is correlated with the severity of coronary artery disease independently of traditional risk factors in young patients. Endokrynol Pol. 2012, 63: 367-371.PubMedGoogle Scholar
- Brownlee M, Cerami A, Vlassara H: Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease. Diabetes Metab Rev. 1988, 4: 437-451. 10.1002/dmr.5610040503View ArticlePubMedGoogle Scholar
- Brownlee M: The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005, 54: 1615-1625. 10.2337/diabetes.54.6.1615View ArticlePubMedGoogle Scholar
- Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005, 353: 2643-2653.View ArticlePubMedGoogle Scholar
- Geluk CA, Post WJ, Hillege HL, Tio RA, Tijssen JG, van Dijk RB, Dijk WA, Bakker SJ, de Jong PE, van Gilst WH, Zijlstra F: C-reactive protein and angiographic characteristics of stable and unstable coronary artery disease: data from the prospective PREVEND cohort. Atherosclerosis. 2008, 196: 372-382. 10.1016/j.atherosclerosis.2006.11.013View ArticlePubMedGoogle Scholar
- Inoue T, Kato T, Uchida T, Sakuma M, Nakajima A, Shibazaki M, Imoto Y, Saito M, Hashimoto S, Hikichi Y, Node K: Local release of C-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting. J Am Coll Cardiol. 2005, 46: 239-245. 10.1016/j.jacc.2005.04.029View ArticlePubMedGoogle Scholar
- Dunn EJ, Philippou H, Ariens RA, Grant PJ: Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia. 2006, 49: 1071-1080. 10.1007/s00125-006-0197-4View ArticlePubMedGoogle Scholar
- Dunn EJ, Ariens RA, Grant PJ: The influence of type 2 diabetes on fibrin structure and function. Diabetologia. 2005, 48: 1198-1206. 10.1007/s00125-005-1742-2View ArticlePubMedGoogle Scholar
- Silbernagel G, Kleber ME, Grammer TB, Winkelmann BR, Boehm BO, Marz W: Additional use of glycated hemoglobin for diagnosis of type 2 diabetes in people undergoing coronary angiography reveals a subgroup at increased cardiovascular risk. Diabetes Care. 2011, 34: 2471-2473. 10.2337/dc11-1046PubMed CentralView ArticlePubMedGoogle Scholar
- Monnier L, Lapinski H, Colette C: Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003, 26: 881-885. 10.2337/diacare.26.3.881View ArticlePubMedGoogle Scholar
- Diedrichs H, Pfister R, Clement Z, Hagemeister J, Schneider CA: Delta-glycated hemoglobin: a novel independent risk factor for cardiovascular events in patients without diabetes mellitus. J Endocrinol Invest. 2009, 32: 564-567. 10.1007/BF03346509View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.